Promotion Center
Press release
Press release
2026-03-24/HLB Life Science Obtains Tissue Bank License, Launches Human Tissue Graft Business
news-p.jpeg (336.6 KB)
HLB Life Science (067630.KQ) said Thursday it has obtained a tissue bank license, marking the full-scale expansion of its human tissue graft business.
The license enables the company to handle human tissues including bone, cartilage, fascia and skin, laying the groundwork to pursue related businesses in earnest.
The approval follows a domestic exclusive distribution agreement signed last month with Orthotech, a medical device specialist, for human tissue grafts. With the tissue bank license as a springboard, HLB Life Science plans to expand its sales network targeting hospitals nationwide and strengthen its market push.
The product HLB Life Science will distribute, "Freedom Inject Refill," is an acellular allogeneic dermal injectable derived from human tissue. It is a human tissue-based product made from acellular dermis. The product is used for treating damaged ligaments, tendons and muscles, as well as supplementing surgical procedures. It can be stored at room temperature, which is expected to enhance convenience in clinical settings.
The product is characterized by the removal of cells and fat components from skin-derived tissue while maximally preserving extracellular matrix (ECM) components such as collagen that are essential for tissue regeneration. This allows it to be applied across a wide range of areas including reconstruction, regeneration and recovery of damaged soft tissue and joints.
HLB Life Science plans to use the tissue bank license as an opportunity to expand its portfolio of human tissue-based products. Initial supply targets include orthopedic surgery, neurosurgery, obstetrics and gynecology, and urology departments at hospitals nationwide. The company plans to gradually broaden its application areas and distribution channels going forward.
"The tissue bank license is highly significant in that we have secured a core foundation to fully launch our human tissue graft business," said Baek Yun-ki, CEO-designate of HLB Life Science. "We will continue to create new growth engines in regenerative medicine, going beyond expanding domestic supply."
Lee, Jung-min. “HLB Life Science Obtains Tissue Bank License, Launchs Human Tissue Graft Business.” Seoul Economic Daily, March 24, 2026.
하단영역
78 Yulam-ro, Dong-gu, Daegu Metropolitan City
- Tel
- +82-53-314-7016
- Fax
- +82-53-314-7017
- orthotech@orthotech.co.kr
100-4, Cheombok-ro, Dong-gu, Daegu (Dongnae-dong)
- Tel
- +82-53-314-7016~5
COPYRIGHT ORTHOTECH. ALL RIGHTS RESERVED. Designed by WebSite.co.kr